Vaccinex Inc., a clinical-stage biotechnology company, has entered into a clinical collaboration agreement with Merck through a subsidiary, to evaluate the combination of Vaccinex’s investigational SEMA4D inhibitor, pepinemab, and Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in the treatment of patients with advanced, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).   “We are pleased to be working with Merck to evaluate the potential of pepinemab in combination wi...